Comparative Pharmacology
Head-to-head clinical analysis: DEMADEX versus LASIX ONYU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMADEX versus LASIX ONYU.
DEMADEX vs LASIX ONYU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Lasix (furosemide) inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption.
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
Furosemide 20-80 mg IV/PO once or twice daily; max 600 mg/day for IV, 80 mg/day for PO.
None Documented
None Documented
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 mL/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
1.5-2.0 hours in normal renal function; prolonged to 10-15 hours in severe renal impairment (CrCl <10 mL/min); clinically significant accumulation risk with repeated dosing in renal disease.
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
Primarily renal (50-80% as unchanged drug); biliary/fecal (20-30%); non-renal clearance accounts for up to 20%.
Category C
Category C
Loop Diuretic
Loop Diuretic